Tobacco use and tobacco services in California substance use treatment programs.
Policy
Smoking cessation
Substance use treatment
Tobacco control
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
01
04
2020
revised:
26
05
2020
accepted:
04
07
2020
pubmed:
22
7
2020
medline:
17
3
2021
entrez:
22
7
2020
Statut:
ppublish
Résumé
California has one of the lowest smoking rates in the U.S. However, the California substance use disorder (SUD) treatment system collects no information on tobacco use. We explored smoking prevalence among persons enrolled in 20 residential SUD treatment programs, and whether persons who wanted help with quitting smoking received such help. Treatment program clients (N = 562) were surveyed about their smoking behavior and about tobacco-related services they received. Self-report smoking status was verified via expired carbon monoxide (CO) measurement. Multivariate analyses assessed whether clients who wanted help with quitting smoking received tobacco-related services (ask, advise, referral, counseling, pharmacotherapy) RESULTS: Using client self-report and expired CO, smoking prevalence in this sample was estimated at 68.9 %. Among smokers, mean cigarettes per day (CPD) was 9.7 (SD = 7.6), 58.8 % had made a quit attempt in the past year, 32.7 % were considering quitting smoking in the next 30 days, and 37.9 % wanted help with quitting. Clients who wanted help with quitting, compared to those not wanting help, were more likely to receive advice on how to quit, and tobacco-related counseling, referral, and pharmacotherapy. In this study, wanting help with quitting was associated with receiving tobacco related services. Nonetheless, fewer than half of the smokers in SUD treatment wanted help with quitting, and many who wanted help did not receive it. Given the high prevalence of smoking, and associated consequences for both general health and SUD recovery, SUD treatment systems should ensure tobacco-related assessment and intervention for all smokers.
Sections du résumé
BACKGROUND
California has one of the lowest smoking rates in the U.S. However, the California substance use disorder (SUD) treatment system collects no information on tobacco use. We explored smoking prevalence among persons enrolled in 20 residential SUD treatment programs, and whether persons who wanted help with quitting smoking received such help.
METHODS
Treatment program clients (N = 562) were surveyed about their smoking behavior and about tobacco-related services they received. Self-report smoking status was verified via expired carbon monoxide (CO) measurement. Multivariate analyses assessed whether clients who wanted help with quitting smoking received tobacco-related services (ask, advise, referral, counseling, pharmacotherapy) RESULTS: Using client self-report and expired CO, smoking prevalence in this sample was estimated at 68.9 %. Among smokers, mean cigarettes per day (CPD) was 9.7 (SD = 7.6), 58.8 % had made a quit attempt in the past year, 32.7 % were considering quitting smoking in the next 30 days, and 37.9 % wanted help with quitting. Clients who wanted help with quitting, compared to those not wanting help, were more likely to receive advice on how to quit, and tobacco-related counseling, referral, and pharmacotherapy.
CONCLUSION
In this study, wanting help with quitting was associated with receiving tobacco related services. Nonetheless, fewer than half of the smokers in SUD treatment wanted help with quitting, and many who wanted help did not receive it. Given the high prevalence of smoking, and associated consequences for both general health and SUD recovery, SUD treatment systems should ensure tobacco-related assessment and intervention for all smokers.
Identifiants
pubmed: 32693199
pii: S0376-8716(20)30338-0
doi: 10.1016/j.drugalcdep.2020.108173
pmc: PMC7439769
mid: NIHMS1614691
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108173Subventions
Organisme : NCI NIH HHS
ID : P30 CA082103
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest At the time the paper was written, Erika Pinsker was an evaluation specialist at CTCP, with oversight responsibility for implementation of the contract funding a portion of the data used in this report. Other authors report no actual or potential conflicts of interest.
Références
Am J Public Health. 2013 Oct;103(10):1799-801
pubmed: 23948006
Prev Chronic Dis. 2012;9:E23
pubmed: 22172190
Am J Prev Med. 2016 May;50(5):573-583
pubmed: 26711164
J Consult Clin Psychol. 2004 Dec;72(6):1144-56
pubmed: 15612860
J Subst Abuse Treat. 2016 Aug;67:22-9
pubmed: 27296658
Prev Chronic Dis. 2019 Feb 07;16:E17
pubmed: 30730828
Addict Behav. 2017 Feb;65:161-170
pubmed: 27816663
J Consult Clin Psychol. 1991 Apr;59(2):295-304
pubmed: 2030191
BMJ Open. 2015 Oct 01;5(10):e008807
pubmed: 26428333
Addiction. 2016 Feb;111(2):220-30
pubmed: 26392127
Subst Abuse Treat Prev Policy. 2017 May 2;12(1):20
pubmed: 28464898
Tob Control. 2003 Dec;12 Suppl 4:IV3-10
pubmed: 14645934
Drug Alcohol Depend. 2017 Nov 1;180:178-192
pubmed: 28910690
J Subst Abuse Treat. 2015 Aug;55:29-38
pubmed: 25805668
J Subst Abuse Treat. 2008 Mar;34(2):165-72
pubmed: 17509809
J Subst Abuse Treat. 2016 Apr;63:39-45
pubmed: 26825975
Am J Drug Alcohol Abuse. 2017 Mar;43(2):215-225
pubmed: 27314884
Tob Induc Dis. 2015 Oct 22;13:33
pubmed: 26500471
J Subst Abuse Treat. 2005 Jun;28(4):331-40
pubmed: 15925267
J Subst Abuse Treat. 2012 Apr;42(3):319-27
pubmed: 22000325
Adm Policy Ment Health. 2016 Mar;43(2):241-9
pubmed: 25677250
Cochrane Database Syst Rev. 2016 Nov 23;11:CD010274
pubmed: 27878808
Tob Control. 2010 Apr;19 Suppl 1:i3-15
pubmed: 20382647
J Subst Abuse Treat. 2017 May;76:64-68
pubmed: 28143680
Am J Public Health. 2012 May;102(5):e17-25
pubmed: 22420814
J Psychoactive Drugs. 2018 Jan-Mar;50(1):3-11
pubmed: 29279040
Drug Alcohol Depend. 2019 Apr 1;197:8-14
pubmed: 30743196
Drug Alcohol Depend. 2016 Sep 01;166:93-9
pubmed: 27449271
Psychiatr Serv. 2019 Mar 1;70(3):229-232
pubmed: 30630403
J Behav Health Serv Res. 2020 Apr;47(2):264-274
pubmed: 31359228
Respir Care. 2008 Sep;53(9):1217-22
pubmed: 18807274
Psychiatr Serv. 2004 Nov;55(11):1258-64
pubmed: 15534014
PLoS One. 2015 Mar 25;10(3):e0120581
pubmed: 25807109
Transl Behav Med. 2019 Mar 1;9(2):319-327
pubmed: 29955886
BMC Health Serv Res. 2014 Jul 14;14:304
pubmed: 25017205
Psychiatr Serv. 2015 Nov;66(11):1213-20
pubmed: 26234332
Nicotine Tob Res. 2016 May;18(5):993-1001
pubmed: 26069036
J Addict Dis. 2020 Jan-Mar;38(1):55-63
pubmed: 32186480
Prev Chronic Dis. 2015 Oct 01;12:E167
pubmed: 26425871
J Addict Med. 2017 Jul/Aug;11(4):273-279
pubmed: 28441272
Nicotine Tob Res. 2020 Jun 12;22(7):1086-1097
pubmed: 31570931